MLKL Gene
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">MLKL Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>MLKL</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>Mixed Lineage Kinase Domain-Like</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>16q23.1</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>83568</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q8TBX5</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000147854</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>RHIM domain-containing pseudo-kinase</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~54 kDa</td>
</tr>
<tr>
<td class="label">Domain</td>
<td>Location</td>
</tr>
<tr>
<td class="label">Four-Helix Bundle (4HB)</td>
<td>N-terminal (1-180)</td>
</tr>
<tr>
<td class="label">Intermediate Domain</td>
<td>(180-290)</td>
</tr>
<tr>
<td class="label">Pseudokinase Domain (KD)</td>
<td>C-terminal (290-480)</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Necrostatin-1</td>
<td>RIPK1 inhibitor</td>
</tr>
<tr>
<td class="label">GW39714</td>
<td>RIPK3 inhibitor</td>
</tr>
<tr>
<td class="label">Compound 18</td>
<td>MLKL direct inhibitor</td>
</tr>
<tr>
<td class="label">Z-VAD-FMK</td>
<td>Pan-caspase inhibitor</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/alzheimer-disease" style="color:#ef9a9a">Alzheimer disease</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">665 edges</a></td>
</tr>
</table>
Pathway Diagram
Mermaid diagram (expand to render)
Introduction
Mlkl Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
MLKL (Mixed Lineage Kinase Domain-Like) is a crucial effector protein in the necroptosis pathway, executing programmed necrotic cell death downstream of Receptor-Interacting Protein Kinase 3 (RIPK3). While originally identified as a pseudokinase due to its lack of canonical kinase activity, MLKL plays an essential role in executing necroptosis—a form of programmed cell death distinct from [apoptosis](/entities/apoptosis) that is characterized by membrane rupture and release of intracellular contents. This page covers the gene structure, protein function, disease associations, and therapeutic implications of MLKL in neurodegenerative diseases. [@wang2014]
Gene Structure
The MLKL gene consists of 10 exons spanning approximately 12 kb of genomic DNA. The gene encodes a protein with 480 amino acids containing an N-terminal four-helix bundle (4HB) domain and a C-terminal pseudokinase domain (KD). The pseudokinase domain retains the ability to bind ATP but lacks catalytic activity, functioning instead as a regulatory domain that interacts with RIPK3.
Multiple splice variants have been identified:
- Isoform 1 (canonical): Full-length 480 amino acids
- Isoform 2: Truncated variant lacking C-terminal domain
Protein Structure and Function
MLKL functions as the key executioner of necroptosis through a well-characterized molecular cascade:
Activation: In response to death receptor ligands (TNF-α, FasL, TRAIL), RIPK1 recruits and activates RIPK3
Phosphorylation: RIPK3 phosphorylates MLKL at Thr357 and Ser358 (human)
Oligomerization: Phosphorylated MLKL undergoes conformational change and forms oligomers
Membrane Translocation: MLKL oligomers translocate to the plasma membrane
Pore Formation: MLKL inserts into the membrane, forming necrotic pores (10-50 nm diameter)
Cell Lysis: Membrane rupture releases DAMPs (damage-associated molecular patterns)Key Domains
Expression Pattern
MLKL is expressed in most human tissues with highest levels in:
- Brain: [Cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), cerebellum, basal ganglia
- Immune system: Lymphocytes, macrophages, dendritic cells
- Cardiovascular: Heart, vascular endothelium
- Gastrointestinal: Intestine, liver
In the brain, MLKL is expressed in:
- [Neurons](/entities/neurons) (particularly cortical pyramidal neurons)
- [Astrocytes](/entities/astrocytes)
- [Microglia](/entities/microglia)
- [Oligodendrocytes](/cell-types/oligodendrocytes)
Role in Neurodegeneration
Alzheimer's Disease
In Alzheimer's disease, MLKL-mediated necroptosis contributes to:
- Amyloid-β induced neuronal death: [Aβ](/proteins/amyloid-beta) oligomers activate RIPK1/RIPK3/MLKL pathway
- [Tau](/proteins/tau) pathology interaction: Hyperphosphorylated [tau](/proteins/tau) enhances necroptotic signaling
- Neuroinflammation: Microglial necroptosis releases pro-inflammatory DAMPs
- Synaptic loss: Necroptotic neurons release synaptic proteins, accelerating pathology
Key Evidence:
- Elevated MLKL phosphorylation in AD brain tissue (postmortem studies)
- Correlation between p-MLKL levels and disease severity
- Genetic deletion of MLKL protects against Aβ toxicity in mouse models
Parkinson's Disease
In Parkinson's disease, MLKL is implicated in:
- Dopaminergic neuron vulnerability: Selective susceptibility of SNpc neurons
- [α-Synuclein](/proteins/alpha-synuclein) toxicity: Pathological α-synuclein activates necroptosis
- Mitochondrial dysfunction: Complex I deficiency enhances MLKL activation
- Neuroinflammation: Microglial necroptosis in PD brains
Key Evidence:
- Increased p-MLKL in PD substantia nigra
- RIPK1/MLKL activation in toxin-based PD models (MPTP, 6-OHDA)
- Protective effects of MLKL knockout in experimental PD
ALS (Amyotrophic Lateral Sclerosis)
- [TDP-43](/proteins/tdp-43) pathology triggers necroptotic pathways
- Mutant SOD1 induces MLKL activation in motor neurons
- Non-cell autonomous toxicity from astrocytic necroptosis
Huntington's Disease
- Mutant [huntingtin](/proteins/huntingtin-protein) protein activates RIPK1/MLKL pathway
- Contributes to striatal neuron degeneration
Therapeutic Targeting
MLKL Inhibitors
Therapeutic Strategies
Direct MLKL inhibition: Small molecules targeting MLKL oligomerization
RIPK3 blockade: Preventing MLKL phosphorylation
Combination therapy: MLKL inhibitors with existing neuroprotective agentsChallenges
- [Blood-brain barrier](/entities/blood-brain-barrier) penetration
- Specificity for neuronal vs immune cell necroptosis
- Timing of intervention in disease progression
Animal Models
- MLKL knockout mice: Viable and fertile, resistant to necroptotic cell death
- Conditional knockouts: Neuron-specific and [microglia](/cell-types/microglia-neuroinflammation)-specific models available
- Transgenic models: Expressing human MLKL mutants
Biomarkers
- p-MLKL (Thr357): Detectable in CSF and blood
- MLKL oligomers: Tissue biomarkers
- [Necroptosis](/entities/necroptosis)-associated DAMPs: HMGB1, S100A9 in circulation
Research Directions
- Developing brain-penetrant MLKL inhibitors
- Biomarker validation for clinical trials
- Combination approaches with anti-amyloid and anti-tau therapies
- Understanding cell-type specific necroptosis mechanisms
Background
The study of Mlkl Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
See Also
- MLKL Protein - Protein product
- RIPK3 Gene - Upstream kinase activating MLKL
- RIPK1 Gene - Initiator kinase
- Necroptosis Pathway - Programmed necrotic cell death
- Neuroinflammation P- [Alzheimer's Disease](/diseases/a- [Parkinson's Disease](/diseases/parkinsons-disease)ing
- [Alzheimer's Disease](/diseases/a- [Parkinson's Disease](/diseases/parkinsons-disease) in AD
- [Parkinson's Disease](/diseases/parkinsons-disease) MLKL in PD
External Links
- [NCBI Gene: MLKL](https://www.ncbi.nlm.nih.gov/gene/83568)
- [UniProt: Q8TBX5](https://www.uniprot.org/uniprot/Q8TBX5)
- [GeneCards: MLKL](https://www.genecards.org/cgi-bin/carddisp.pl?gene=MLKL)
- [OMIM: MLKL](https://www.omim.org/entry/614396)
References
[Sun L, et al, (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22265413/)
[Wang H, et al, (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/24709636/)
[Caccamo A, et al, (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28232766/)
[Iannielli A, et al, (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29605867/)
[Qin D, et al, (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31034628/)
[Zhang S, et al, (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32857213/)
[Liu Y, et al, (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34289456/)
[Wang Z, et al, (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35691578/)Pathway Diagram
The following diagram shows the key molecular relationships involving MLKL Gene discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)